79 filings
Page 4 of 4
8-K
f0yrb6y7b92u89t zoep
15 Oct 19
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
8:03am
8-K
2yl60623law6fdmcv5gt
24 Sep 19
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:05pm
8-K
p6t spzlino5
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
au218y
13 Aug 19
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
4:05pm
8-K
6x8fe l2t3e
1 Jul 19
Other Events
8:02am
8-K
yh6gn 1qvj9drjgv066k
17 Jun 19
Other Events
4:05pm
8-K
by9089lu74owgfn 6l
13 May 19
Submission of Matters to a Vote of Security Holders
12:00am
8-K
tbh2uhxdwnro92 7cq4
9 May 19
PhaseBio Reports First Quarter 2019 Financial and Business Results
4:05pm
8-K
w7r31m kxjco
10 Apr 19
Regulation FD Disclosure
8:00am
8-K
09r0m0nh0
9 Apr 19
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
8:01am
8-K
0da6p4ubtwucgdee7tb
8 Apr 19
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:25pm
8-K
oqr1t3icvs72
4 Apr 19
Entry into a Material Definitive Agreement
4:05pm
8-K
9yubmf
26 Mar 19
PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results
4:05pm
8-K
njbwv5sry
21 Mar 19
PB2452 achieved immediate and sustained reversal of ticagrelor antiplatelet effects
4:05pm
8-K
ce8 nt7vovk00baq
4 Mar 19
PhaseBio Appoints Richard A. van den Broek to Board of Directors
8:00am
8-K
uy0a6j8z3v6t26
25 Jan 19
Material Modifications to Rights of Security Holders
4:05pm
8-K
f76lentg7 nvshz7b3qh
17 Dec 18
PhaseBio Appoints Edmund P. Harrigan to Board of Directors
4:36pm
8-K
19ltgtt m0yocjgy90hc
29 Nov 18
PhaseBio Reports Third Quarter 2018 Financial and Business Results
4:41pm
8-K
rs0nusx5 2a
22 Oct 18
Amendments to Articles of Incorporation or Bylaws
4:34pm